Exclusive event will showcase the latest innovations in longevity science and consumer diagnostics and focus on investment opportunities.
The Founders Longevity Forum London (FLF:LN) will return on 10th June 2025, at OXO2, one of London’s most striking riverside venues. Held during London Tech Week, the event, which is organized by Longevity.Technology and Founders Forum, will bring together a select group of founders, investors and industry leaders to explore the rapidly evolving longevity sector.
A curated forum for senior-level dialogue
The forum maintains a carefully balanced mix of investors and founders, ensuring discussions remain focused on advancing longevity technologies and supporting the sector’s growth. With attendance strictly limited, participants will engage in high-level conversations on the scientific, clinical and commercial developments shaping the industry.
FLF:LN 2025 follows the success of the previous London forum and will build on the momentum generated at Founders Longevity Forum Singapore earlier this year. The event is designed to foster collaboration between those at the forefront of longevity research and those driving investment in this rapidly expanding field.
Founders Forum Group CEO Carolyn Dawson told Longevity.Technology the team is excited to be bringing the Founders Longevity Forum back to London for 2025. “As the appetite for longevity investment continues to grow, this forum provides a vital platform to connect investors with the most promising scientific and commercial opportunities in healthy aging,” she said. “With momentum building globally, our mission remains to foster meaningful partnerships that drive longevity innovation forward.”
Scientific progress, consumer demand and the investment landscape
The longevity sector continues to attract increasing interest from both researchers and investors; breakthroughs in consumer diagnostics, biohacking innovations and specialised clinics are reshaping perceptions of aging and preventive healthcare, and as companies develop new therapeutics and interventions aimed at extending healthspan, the need for strategic investment and regulatory clarity has become increasingly evident.
Against this backdrop, FLF:LN provides a platform for scientists, entrepreneurs and investors to examine the latest research, discuss commercialization strategies and explore opportunities to accelerate innovation. Attendees can expect rigorous discussions on the challenges of translating longevity science into viable consumer and clinical applications, with particular focus on how companies can navigate regulatory frameworks and scale their operations.
Confirmed speakers and topics of discussion
The forum will feature leading figures from longevity biotechnology, precision medicine and venture capital. While the full speaker lineup will be announced in the coming months, we can already confirm the following:
- Amol Sarva – Managing Partner, LifeX
- Daniel Ives – CEO & Founder, Shift Bioscience
- Erin Lee – Founder & CEO, Touchless Wellness Association
- Laura Deming – CEO, Cradle; Cofounder & Venture Partner, age1; Founder, Longevity Fund
- Nils Regge – Cofounder & General Partner, Apollo Health Ventures
- Will Harborne – Founding Partner & GP, LongGame Ventures
More prominent voices from across the industry will be added to the line-up soon, all offering perspectives on emerging technologies, clinical validation and funding strategies.
Discussions will cover a range of key topics, including:
- The latest advances in cellular and epigenetic reprogramming.
- AI-driven drug discovery and personalised longevity interventions.
- The role of biomarker-driven consumer diagnostics in preventive health.
- Strategies for scaling longevity startups in a rapidly evolving regulatory environment.
- Investment trends shaping the future of specialised longevity clinics and therapeutics.
A critical moment for the longevity sector
The past decade has seen a rapid acceleration in scientific discoveries related to aging and lifespan extension – however, the challenge remains in translating these advancements into real-world applications. As consumer interest grows and investors seek scalable business models, events like FLF:LN 2025 offer an opportunity to examine which technologies have genuine commercial potential and how they can be integrated into mainstream healthcare and wellness markets.
The longevity space is now at an inflection point – significant capital is being deployed, regulatory frameworks are evolving and major players from biotechnology and healthcare are moving into the field. The forum will address how investors and founders can navigate this landscape while ensuring scientific integrity and ethical considerations remain at the forefront.
Phil Newman, Founder and CEO of Longevity.Technology told us that longevity sector investment more than doubled from $3.76bn in 2023 to $8.26bn in 2024. “This shows the positive trajectory that we all want to see but we’re still seeing a lack of Seed and Series A capital entering the space and this is what Founders Longevity Forum is leaning into,” he explained. “We want to educate investors on the opportunity by learning from global expert presenters, meeting with investors who are already activating longevity investments, and discovering the pioneer companies that are raising capital to scale. We had a great event in London last year, Singapore was truly incredible, and I’m even more excited about our London event in June.”
Limited space for a highly selective audience
Given the curated nature of the forum, places are limited, and registration requests will be reviewed based on relevance to the event’s core themes. This ensures a focused, high-value experience for all attendees, facilitating meaningful discussions and potential collaborations between leading figures in the field.
Those interested in participating in Founders Longevity Forum London 2025 are encouraged to register their interest, as demand for places is expected to be high. Further details, including additional speaker announcements and agenda updates, will be released in the coming months, so stay tuned!
